Dario Alimonti

Dr. Dario Alimonti

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 October 2020 in Electronics
Verified
Journal Article
Open access
PDF file
Patrick LocatelliPatrick Locatelli
Patrick Locatelli
DADario Alimonti
Dario Alimonti
Gianluca TraversiGianluca Traversi
Gianluca Traversi
Valerio ReValerio Re
Valerio Re
Among movement disorders, essential tremor is by far the most common, as much as eight times more prevalent than Parkinson’s disease. Although these two conditions differ in their presentation and course, clinicians do not always recognize them, leading to common misdiagnoses. Proper and early diagnosis is important for receiving the right treatment and support. In this paper, the development of a portable and reliable tremor classification system based on a wearable device, enabling clinicians to differentiate between essential tremor and Parkinson’s disease-associated one, is reported. Inertial data were collected from subjects with a well-established diagnosis of tremor, and analyzed to extract different sets of relevant spectral features. Supervised learning methods were then applied to build several classification models, among which the best ones achieved an average accuracy above 90%. Results encourage the use of wearable technology as effective and affordable tools to support clinicians.

1 September 2020 in Brain Stimulation
Verified
Journal Article
Open access
DADario Alimonti
Dario Alimonti
RDR. Donati
R. Donati
CFC. Foresti
C. Foresti
OMO. Manara
O. Manara
MSM. Sessa
M. Sessa

20 November 2025 in Sensors
Verified
Journal Article
Open access
PDF file
RZROSALIA ZANGARI
ROSALIA ZANGARI
LBLaura Brighina
Laura Brighina
APAndrea Pilotto
Andrea Pilotto
GCGreta Carioli
Greta Carioli
Vincenzo D’AgostinoVincenzo D’Agostino
Vincenzo D’Agostino
DADario Alimonti
Dario Alimonti
Gait assessment is key in Parkinson’s disease (PD), but the psychometric properties of common tests like the 6-Minute Walk Test (6MWT) are not fully established. Inertial Measurement Units (IMUs) offer objective gait measures, potentially reducing repeated testing. This study evaluated whether the resampling of the first 2 min of the 6MWT (2’6MWT) reflects full-test performance in 43 early-to-mild PD patients (median age 65) at baseline, 1-year, and 2-year follow-ups. A trunk-mounted IMU recorded distance covered, walking duration, stride length, gait speed, cadence, and symmetry. Analysis focused on participants with complete longitudinal data from a multicenter original cohort of 62. Stride length and gait speed (2’6MWT vs. 6MWT) demonstrated strong correlations (r > 0.98), near-perfect agreement, <5% error, and stability across follow-ups; cadence showed slightly more variability. The analysis of consecutive 2-min intervals of the 6MWT revealed stable stride length and gait speed, with modest decreases in distance and cadence over time. Exploratory associations of 2’6MWT and 6MWT with motor severity and cognitive status were consistent. These results indicate the 2’6MWT is a reliable, time-efficient alternative to the full 6MWT for assessing walking capacity in PD, especially in outpatient or fatigue-prone patients. The full 6MWT remains valuable for detecting subtle endurance- or fatigue-related changes.

1 January 2025 in Case Reports in Neurological Medicine
Verified
Journal Article
Open access
MSManlio Sgarzi
Manlio Sgarzi
PPPaolo Paone
Paolo Paone
PGPaolo Gritti
Paolo Gritti
EAEmanuela Agazzi
Emanuela Agazzi
GCGiorgia Camera
Giorgia Camera
DADario Alimonti
Dario Alimonti
Introduction: Generalized myasthenia gravis (gMG) is an autoimmune disorder impairing neuromuscular transmission, most commonly through anti‐AChR antibodies that activate the complement cascade. This can lead to severe complications such as myasthenic crisis (MC), which often requires intensive care. While plasma exchange (PLEX) and intravenous immunoglobulins (IVIG) are standard first‐line therapies, approximately 30% of patients may show suboptimal response. Ravulizumab, a long‐acting C5 complement inhibitor, has been approved for anti‐AChR‐positive gMG, but data on its use in MC remain limited. Case Presentation: We report a 62‐year‐old male with late‐onset, anti‐AChR‐positive gMG who presented with refractory MC, unresponsive to five PLEX sessions and IVIG. After infectious disease evaluation, meningococcal prophylaxis, and antibiotic coverage, a single intravenous loading dose of ravulizumab (2700 mg) was administered on ICU Day 9. Clinical Response: Marked clinical improvement was observed within 48 h, including reduction in ventilatory support (pressure support decreased from 16 to 6 cmH 2 O over five days), improved cough, secretion management, and eventual successful extubation on Day 17. By Day 21, the patient resumed oral feeding and was transferred out of ICU with stable respiratory function and neurological improvement. Conclusion: This case suggests that ravulizumab may provide rapid and sustained benefit in anti‐AChR‐positive patients experiencing refractory MC. Complement inhibition led to early ventilatory and neuromuscular recovery despite prior treatment failure. These findings support further investigation of ravulizumab as rescue therapy in acute, treatment‐resistant gMG exacerbations.

1 November 2026 in Stroke
Verified
Journal Article
Closed access
GSGhil Schwarz
Ghil Schwarz
ARAngelo Cascio Rizzo
Angelo Cascio Rizzo
GAGareth Ambler
Gareth Ambler
PWPawel Wrona
Pawel Wrona
ASAgnieszka Slowik
Agnieszka Slowik
MSMaria Sessa
Maria Sessa
BACKGROUND: Contrast-associated acute kidney injury (CA-AKI) after endovascular thrombectomy (EVT) worsens outcomes in acute ischemic stroke, but threshold-based definitions do not capture prognostic information from subthreshold changes. We tested whether early creatinine change within 48 hours of EVT conveys graded prognostic information beyond dichotomous CA-AKI. METHODS: We performed a secondary analysis of the CAN-REST registry (Contrast-Associated Nephropathy After Endovascular Stroke Treatment), a retrospective multicenter observational cohort study of 6638 EVT-treated adults with acute ischemic stroke enrolled at 73 centers in 16 countries between January 1 and December 31, 2023. Early creatinine change was quantified as the natural logarithm ratio of 48-hour creatinine to baseline creatinine (ln[48-hour/baseline creatinine]), with CA-AKI defined per Kidney Disease: Improving Global Outcomes criteria (≥0.3 mg/dL or ≥1.5× baseline rise within 48 hours). Multivariable logistic regression adjusted for prespecified baseline and periprocedural covariates examined associations with 90-day modified Rankin Scale shift and in-hospital mortality; linear versus restricted cubic spline specification was selected by likelihood ratio testing, and contrasts were estimated at ±10%, ±25%, and ±50%. RESULTS: Greater creatinine worsening within 48 hours of EVT was independently associated with an unfavorable 90-day modified Rankin Scale shift (adjusted common odds ratio per 1-unit log-ratio increase, 1.48 [95% CI, 1.07–2.04]; linear) and in-hospital mortality (nonlinear dose-response, of larger magnitude). A 10% increase in creatinine at 48 hours—well below Kidney Disease: Improving Global Outcomes threshold—was associated with worse functional outcome (adjusted common odds ratio, 1.04 [95% CI, 1.01–1.07]) and death (adjusted odds ratio, 1.22 [95% CI, 1.13–1.32]); a 10% decrease in creatinine at 48 hours was associated with lower odds of both outcomes (adjusted common odds ratio, 0.96 [95% CI, 0.93–0.99]; adjusted odds ratio, 0.74 [95% CI, 0.65–0.86]). The functional-outcome association concentrated at upper modified Rankin Scale cut-points (severe disability, death); effect modification by baseline renal function was not significant. CONCLUSIONS: Early creatinine change after EVT conveys graded, outcome-specific prognostic information extending below formal CA-AKI thresholds, with a dose-response detectable at changes as modest as ±10%, complementing binary CA-AKI as a framework for post-EVT renal risk assessment. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT06596603.